José Adélaide

José Adélaide

Auto-generated profile, based on publicly available information

José Adélaide

Laboratoire d'Oncologie Pr edictive, Centre de Recherche en Canc erologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille Universit e U105, Institut Paoli-Calmettes, Label « Ligue contre le cancer », Marseille, France

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2022 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
OCOlivier Cabaud
Olivier Cabaud
LBLudovic Berger
Ludovic Berger
ECEmerence Crompot
Emerence Crompot
JAJosé Adélaide
José Adélaide
PFPascal FINETTI
Pascal FINETTI
MLMarc Lopez
Marc Lopez
Antibody–drug conjugates (ADC) represent a fast-growing drug class in oncology. However, ADCs are associated with resistance, and therapies able to overcome it are of utmost importance. Recently, enfortumab vedotin-ejfv (EV) was approved in nectin-4+ metastatic urothelial cancer. We previously described PVRL4/nectin-4 as a new therapeutic target in breast cancer and produced an efficient EV-like ADC comprising a human anti–nectin-4 mAb conjugated to monomethyl auristatin-E (MMAE) named N41mab-vcMMAE. To study the consequence of the long-term treatment with this ADC, we developed a preclinical breast cancer model in mice, and report a mechanism of resistance to N41mab-vcMMAE after 9-month treatment and a way to reverse it. RNA-sequencing pointed to an upregulation in resistant tumors of ABCB1 expression, encoding the multidrug resistance protein MDR-1/P-glycoprotein (P-gp), associated with focal gene amplification and high protein expression. Sensitivity to N41mab-vcMMAE of the resistant model was restored in vitro by P-gp pharmacologic inhibitors, like tariquidar. P-gp is expressed in a variety of normal tissues. By delivering the drug to the tumor more specifically than classical chemotherapy, we hypothesized that the combined use of ADC with P-gp inhibitors might reverse resistance in vivo without toxicity. Indeed, we showed that the tariquidar/N41mab-vcMMAE combination was well tolerated and induced a rapid regression of ADC-resistant tumors in mice. In contrast, the tariquidar/docetaxel combination was toxic and poorly efficient. These results show that ABC transporter inhibitors can be safely used with ADC to reverse ADC-induced resistance and open new opportunities in the fight against multidrug resistance.

3 April 2023
Verified
Other
Open access
OCOlivier Cabaud
Olivier Cabaud
LBLudovic Berger
Ludovic Berger
ECEmerence Crompot
Emerence Crompot
JAJosé Adélaide
José Adélaide
PFPascal FINETTI
Pascal FINETTI
MLMarc Lopez
Marc Lopez
Supplementary Figure from Overcoming Resistance to Anti–Nectin-4 Antibody-Drug Conjugate

3 April 2023
Verified
Other
Open access
OCOlivier Cabaud
Olivier Cabaud
LBLudovic Berger
Ludovic Berger
ECEmerence Crompot
Emerence Crompot
JAJosé Adélaide
José Adélaide
PFPascal FINETTI
Pascal FINETTI
MLMarc Lopez
Marc Lopez
Supplementary Figure from Overcoming Resistance to Anti–Nectin-4 Antibody-Drug Conjugate

3 April 2023
Verified
Other
Open access
OCOlivier Cabaud
Olivier Cabaud
LBLudovic Berger
Ludovic Berger
ECEmerence Crompot
Emerence Crompot
JAJosé Adélaide
José Adélaide
PFPascal FINETTI
Pascal FINETTI
MLMarc Lopez
Marc Lopez
Supplementary Figure from Overcoming Resistance to Anti–Nectin-4 Antibody-Drug Conjugate

3 April 2023
Verified
Other
Open access
OCOlivier Cabaud
Olivier Cabaud
LBLudovic Berger
Ludovic Berger
ECEmerence Crompot
Emerence Crompot
JAJosé Adélaide
José Adélaide
PFPascal FINETTI
Pascal FINETTI
MLMarc Lopez
Marc Lopez

3 April 2023
Verified
Other
Open access
OCOlivier Cabaud
Olivier Cabaud
LBLudovic Berger
Ludovic Berger
ECEmerence Crompot
Emerence Crompot
JAJosé Adélaide
José Adélaide
PFPascal FINETTI
Pascal FINETTI
MLMarc Lopez
Marc Lopez
Supplementary Data from Overcoming Resistance to Anti–Nectin-4 Antibody-Drug Conjugate